Dogma Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Dogma Therapeutics General Information
Description
Operator of a biotechnology platform intended to develop small molecule compounds to lower cholesterol. The company's platform focuses on offering an orally-bioavailable small molecule proprotein convertase subtilisin or Kexin type 9 PCSK9 inhibitor by focusing on small molecule inhibitors, enabling clients to disrupt the health economics of PCSK9-based therapies.
Contact Information
Website
www.dogmatherapeutics.comCorporate Office
- 4 Dana Road
- Boxford, MA 01921
- United States
Corporate Office
- 4 Dana Road
- Boxford, MA 01921
- United States
Dogma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 17-Sep-2020 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 26-Aug-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC | Completed | Startup | ||||
| 2. Early Stage VC (Series A) | 02-May-2017 | $1.5M | $3.5M | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Jan-2017 | $2M | $2M | Completed | Startup |
Dogma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
Dogma Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dogma Therapeutics Patents
Dogma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020150473-A2 | Pcsk9 inhibitors and methods of use thereof | Inactive | 18-Jan-2019 | ||
| WO-2020150474-A1 | Pcsk9 inhibitors and methods of use thereof | Inactive | 18-Jan-2019 |
Dogma Therapeutics Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CR Capital Group | Corporation | Minority | ||
| Changrong Capital | Venture Capital | Minority | ||
| Daoyuan Capital | Venture Capital | Minority | ||
| JMCR Family Office | Family Office | Minority | ||
| Sprout Bioventures | Venture Capital | Minority |
Dogma Therapeutics FAQs
-
When was Dogma Therapeutics founded?
Dogma Therapeutics was founded in 2015.
-
Where is Dogma Therapeutics headquartered?
Dogma Therapeutics is headquartered in Boxford, MA.
-
What industry is Dogma Therapeutics in?
Dogma Therapeutics’s primary industry is Drug Discovery.
-
Is Dogma Therapeutics a private or public company?
Dogma Therapeutics is a Private company.
-
What is Dogma Therapeutics’s current revenue?
The current revenue for Dogma Therapeutics is .
-
How much funding has Dogma Therapeutics raised over time?
Dogma Therapeutics has raised $3.5M.
-
Who are Dogma Therapeutics’s investors?
CR Capital Group, Changrong Capital, Daoyuan Capital, JMCR Family Office, and Sprout Bioventures are 5 of 7 investors who have invested in Dogma Therapeutics.
-
When was Dogma Therapeutics acquired?
Dogma Therapeutics was acquired on 17-Sep-2020.
-
Who acquired Dogma Therapeutics?
Dogma Therapeutics was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
